Press release Full year and fourth quarter 2020 - GSK

* Reported AER and CER growth rates for 2020 include five months’ results of the former Pfizer consumer healthcare business in 2019. Pro-forma CER growth rates are calculated as if the equivalent seven months of Pfizer consumer healthcare business results, as reported by Pfizer, were included in the comparative period of 2019.

  Pfizer

Financial statements - GSK

The Group financial statements for the year ended . 31 December 2020, comprising principal statements and supporting notes, are set out in the ‘Financial statements’ on pages 154 to 237 of this report. The parent company financial statements for the year ended 31 December 2020, comprising the balance sheet and the statement of changes in

  Testament, Financial, Financial statements

Emma Walmsley, CEO - gsk.com

Agenda 2 Q2 2018 progress (15 mins) Emma Walmsley, Chief Executive Officer Q2 2018 financial results (15 mins) Simon Dingemans, Chief Financial Officer

  Mame

Audit & Risk Committee Terms of Reference - Home | GSK

Audit & Risk Committee – Terms of Reference 2 3. Each of the members of the Committee shall be independent Non-Executive Directors, as determined by the Board of the Company, in accordance with the provisions of the UK Corporate

  Terms, Risks, Reference, Committees, Audit, Terms of reference audit amp risk committee

Press release Third quarter 2021

Issued: Wednesday, 27 October 2021, London, U.K. 3 Operating performance – Q3 2021 Turnover Q3 2021 £m Growth £% Growth CER% Pharmaceuticals 4,397 5 10 Vaccines 2,174 7 13 Consumer Healthcare 2,506 3 8 Group turnover 9,077 5 10 Group turnover was £9,077 million in the quarter, up 5% AER, 10% CER.

  October, 27 october

Q3 2021 results

Progressing towards demerger at pace. 8. 1. All outlook and ambition statements are given on a constant currency basis and use 2021 forecast exchange rates as a base, assuming a continuation of Q1 2021 closing rates. 2021-26 CAGR is for the 5 …

Annual Report 2018 - GSK

GSK Annual Report 2018 02. Research & development . Success in R&D will always be fundamental to shareholder returns. A renewed focus on R&D was set out by Emma Walmsley when she became CEO in 2017, and a new plan to improve the pipeline of new medicines has now been launched by Dr Hal Barron, our new Chief

  Annual, Report, 2018, 2018 annual report, Gsk annual report 2018

Annual Report 2019 - GSK

Trust We are a responsible company and commit to use our science and technology to address health needs, make our products affordable and available and to be a modern employer. Our values and expectations Our values – patient focus, transparency, respect and integrity. Our expectations – courage, accountability, development and teamwork.

  Trust, Annual, Report, Annual report, Affordable

Annual Report 2020 - GSK

framework, we invest in our business to provide shareholder returns. In 2020 we paid a dividend of 80p per share and delivered £5.4 billion of free cash flow. We make a positive contribution to the communities in . which we operate. We employ over 94,000 people across 96 countries and work directly with 36,000 suppliers.

  Annual, Report, Return, 2200, Shareholders, 2002 annual report, Shareholder returns

ESG Performance Summary 2020 - GSK

Employee turnover Overall turnover (%) – – 12.5 15.7 Calculated as the number of permanent employees that left GSK in 2020 for any reason divided by the average 2020 permanent headcount. Turnover of voluntary leavers (%) – – 6.7 5.6 Calculated as the number of permanent employees that voluntarily left GSK in 2020

  Performance, Employee, Summary, 2200, Turnover, Employee turnover, Esg performance summary 2020

Consolidated Financial Results for the Nine Months Ended ...

Nine months ended December 31, 2020 Nine months ended December 31, 2021 % change Total revenue: Digital Entertainment ¥ 144,633 ¥ 153,959 6 .4 Amusement 1 1,266 1 3,709 2 1.7 Gaming & Systems 1 1,754 1 8,680 5 8.9 Sports 2 5,925 3 0,692 1 8.4 Intersegment elimination s (1,648 ) (1,992) -

  Month, Nine, Ended, Nine months ended

FORM 10-Q

Three Months Ended Nine Months Ended October 31, October 25, October 31, October 25, 2021 2020 2021 2020 Net income $ 2,464 $ 1,336 $ 6,749 $ 2,875 Other comprehensive income (loss), net of tax Available-for-sale securities: Net change in unrealized gain (loss) (4) (1) (5) 3 Reclassification adjustments for net realized gain (loss) included in

  Month, Nine, Ended, Months ended nine months ended

Narmada Macplast Drip Systems

9 Months Ended Year Ended Particulars 31/12/2021 31/03/2021 Plant and assets under Assets other than bearer Financial Assets Investments uy Loans 58.22 101.325 0.48 Deferred tax assets (net assets Total Non-Current Assets Assets Financial Assets Investments T Cash and cash Bank Loans Others Tax Other current assets

  Month, Ended, Months ended